Core Viewpoint - The company expects a significant increase in net profit for the first half of 2025, driven by reduced non-recurring factors and the approval of new drugs [1][2]. Group 1: Financial Performance - The company anticipates a net profit of 170 to 210 million yuan for the first half of 2025, representing a year-on-year growth of 94.49% to 140.25%, primarily due to the diminishing impact of non-recurring gains from 2024 [2]. - The expected growth in net profit excluding non-recurring items is projected to be between 3.64% and 26.67% [2]. - Revenue forecasts for 2025 to 2027 are estimated at 2.712 billion, 2.997 billion, and 3.290 billion yuan, respectively, with corresponding EPS of 0.39, 0.49, and 0.60 yuan [4]. Group 2: Product Development - The company has received approval for its innovative drug, Angladiwe, which is the world's first RNA polymerase PB2 protein inhibitor for influenza, expected to contribute to future growth [2]. - Angladiwe is the only anti-influenza drug in China that has undergone head-to-head phase III clinical trials with Oseltamivir, showing a nearly 10% reduction in median time to fever relief compared to Oseltamivir [2]. - The company is rapidly advancing its GLP-1/GIP dual receptor agonist, RAY1225, which has shown promising results in weight loss and metabolic improvement, with ongoing phase III clinical trials in China [3]. Group 3: Market Potential - RAY1225 has potential for international licensing and is positioned to compete effectively in the market, with a higher weight loss achievement rate compared to existing treatments [3][4]. - The company plans to participate in the 2025 medical insurance negotiations for Angladiwe, and is also developing a pediatric formulation of the drug, which has shown favorable results in phase II clinical trials [2].

Core Viewpoint - The legal opinion letter from Beijing Hairun Tianrui Law Firm confirms the adjustment of the repurchase price for the 2022 Restricted Stock Incentive Plan of Guangdong Zhongsheng Pharmaceutical Co., Ltd. The adjustment is in compliance with relevant laws and regulations, and has received necessary approvals [2][12]. Group 1: Adjustment Details - The repurchase price for the restricted stock has been adjusted from 4.98 RMB per share to 4.78 RMB per share due to the company's profit distribution plan [9][12]. - The adjustment was made following the company's 2024 annual profit distribution plan, which included a cash dividend of 2.00 RMB per 10 shares [8][11]. - The adjustment method used was P = P0 - V, where P0 is the original repurchase price and V is the cash dividend per share [11][12]. Group 2: Approval Process - The adjustment received approval from the company's board of directors and supervisory board during meetings held on April 24, 2025, and was subsequently ratified at the annual general meeting on May 19, 2025 [7][8]. - The necessary authorizations for the adjustment were obtained according to the company's first extraordinary general meeting in 2022, thus not requiring further shareholder approval [12]. Group 3: Legal Compliance - The law firm conducted a thorough review of relevant documents, including the draft of the incentive plan and management measures, ensuring that the adjustment complies with the Company Law, Securities Law, and the Management Measures for Listed Company Equity Incentives [3][12]. - The law firm confirmed that all documents provided were authentic and complete, and that the conclusions drawn in the legal opinion are accurate and lawful [4][12].

Core Viewpoint - The company has adjusted the repurchase price of the restricted stock incentive plan for 2022 to 4.7800 CNY per share due to the implementation of the 2024 annual profit distribution plan [1][4][5]. Summary by Sections Repurchase Price Adjustment - The repurchase price for the restricted stock was initially set at 4.9800 CNY per share and has been adjusted to 4.7800 CNY per share following the annual profit distribution [4][5]. - The adjustment is based on the cash dividend of 2.00 CNY per 10 shares distributed to shareholders, which amounts to a total cash dividend of 170,311,295.40 CNY [1][5]. Approval Process - The adjustment was approved during the 24th meeting of the 8th Board of Directors and the 24th Supervisory Board meeting held on July 16, 2025 [4][6]. - Prior approvals were obtained during the 20th meetings of the Board and Supervisory Board on April 24, 2025, and the annual shareholders' meeting on May 19, 2025 [2][3][4]. Impact on the Company - The adjustment of the repurchase price is not expected to have a significant impact on the company's financial status or operational results [5][6]. - The management team will continue to fulfill their responsibilities diligently to create value for shareholders [5]. Legal Compliance - The adjustment has been deemed legal and effective, complying with relevant laws and regulations regarding stock incentive plans [6].

Core Viewpoint - The company has successfully completed the first lock-up period of its 2024 employee stock ownership plan, allowing 45 eligible participants to unlock 30% of the initially granted shares, totaling 1.467 million shares, which represents 0.17% of the company's total share capital [2][7]. Implementation of Employee Stock Ownership Plan - The company held board meetings on June 14, 2024, and July 1, 2024, to approve the implementation of the employee stock ownership plan [2]. - On July 16, 2024, the company transferred 5.551 million shares to the dedicated account for the employee stock ownership plan, which accounted for 0.65% of the total share capital at that time [3]. - The stock ownership plan has three unlocking phases, with the first phase's unlocking conditions met on July 16, 2025 [3][4]. Performance Assessment - The performance assessment for the first lock-up period included company-level targets for revenue and innovation drug development progress [4]. - The company achieved its innovation drug development goals, with significant progress in clinical trials for multiple drugs, resulting in a 100% unlocking ratio for this performance metric [5][6]. - Individual performance assessments for the 45 participants were all rated B+ or above, meeting the criteria for full unlocking [7]. Future Arrangements - Following the unlocking of the first lock-up period, the employee stock ownership management committee will manage the rights of the participants according to the authorized decisions made in the meetings [8]. - The company will adhere to market trading rules and relevant regulations regarding stock transactions [8].

证券代码：002317 公告编号：2025-075 关于调整 2022 年限制性股票激励计划回购价格的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日召开 第八届董事会第二十四次会议，审议通过了《关于调整 2022 年限制性股票激励 计划回购价格的议案》。根据公司已实施的 2024 年年度权益分派方案，公司对 2022 年限制性股票激励计划的限制性股票回购价格进行调整，本次限制性股票 回购价格调整为 4.7800 元/股。具体如下： 一、本次回购注销部分限制性股票的审批程序 （一）2025 年 4 月 24 日，公司第八届董事会第二十次会议和第八届监事会 第二十次会议审议通过了《公司 2024 年度利润分配预案》及《关于 2022 年限制 性股票激励计划第三期解除限售条件未成就暨回购注销部分限制性股票的议案》： 1、公司 2024 年度利润分配预案为：以公司 2024 年 12 月 31 日总股本 851,556,477 股为基数，向全体股东每 10 股派发现金红利 2.00 ...

北京海润天睿律师事务所 关于广东众生药业股份有限公司 调整 2022 年限制性股票激励计划回购价格的 法律意见书 中国·北京 朝阳区建外大街甲14号广播大厦5层、9层、10层、13层、17层 北京海润天睿律师事务所（以下简称"本所"）接受广东众生药业股份有限公 司（以下简称"众生药业"或"公司"）的委托，担任公司"2022 年限制性股票激励计 划"（以下简称"本激励计划"）的法律顾问。根据现行有效适用的《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"） 等有关法律法规的规定，为公司调整 2022 年限制性股票激励计划回购价格（以 下简称"本次调整"）相关事项，出具本法律意见书。 为出具本法律意见书，本所律师审阅了《广东众生药业股份有限公司2022 年限制性股票激励计划（草案）》（以下简称"《激励计划》"）、《广东众生药 业股份有限公司2022年限制性股票激励计划实施考核管理办法》（以下简称"《考 核管理办法》"）、相关股东大会会议文件、董事会会议文件、监事会会议文件 以及本所律师认为需要审查的其他 ...

证券代码：002317 公告编号：2025-074 广东众生药业股份有限公司 关于公司 2024 年员工持股计划预留份额分配的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日召 开第八届董事会第二十四次会议，审议通过了《关于公司 2024 年员工持股计划 预留份额分配的议案》，同意公司 2024 年员工持股计划（以下简称"本员工持 股计划"）的预留份额分配方案。根据本员工持股计划、《广东众生药业股份 有限公司 2024 年员工持股计划管理办法》（以下简称"《管理办法》"）的规 定，本次预留份额分配事项在董事会审批权限范围内，无需提交股东大会审议。 现将有关情况公告如下： 一、本次员工持股计划的实施情况 （一）公司于 2024 年 6 月 14 日召开了第八届董事会第十四次会议和第八 届监事会第十四次会议，于 2024 年 7 月 1 日召开了 2024 年第一次临时股东大 会，分别审议通过了《关于<广东众生药业股份有限公司 2024 年员工持股计划 （草案）>及其摘要的议案》《 ...

证券代码：002317 公告编号：2025-073 广东众生药业股份有限公司 关于公司 2024 年员工持股计划首次授予部分 第一个锁定期届满暨解锁条件成就的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日召 开第八届董事会第二十四次会议，审议通过《关于公司 2024 年员工持股计划首 次授予部分第一个锁定期解锁条件成就的议案》，公司 2024 年员工持股计划 （以下简称"本员工持股计划"）首次授予部分第一个锁定期于 2025 年 7 月 16 日届满。根据本员工持股计划的相关规定，董事会认为本员工持股计划首次授 予部分第一个锁定期解锁条件已经成就，除一名持有人因离职不符合条件外， 本员工持股计划首次授予部分第一个锁定期可解锁的持有人共 45 名，本次解锁 比例为本员工持股计划首次授予部分的 30%，可解锁的标的股票数量为 146.70 万股，占公司目前总股本的 0.17%。离职员工对应的股票份额由本员工持股计 划管理委员择机出售，所获得的资金归属于公司，公司扣除该部分现金分红 ...

证券代码：002317 公告编号：2025-072 广东众生药业股份有限公司 第八届监事会第二十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届监事会第二十四次 会议的会议通知于 2025 年 7 月 9 日以专人和电子邮件方式送达全体监事，会议 于 2025 年 7 月 16 日在公司会议室以现场和通讯表决方式召开。本次会议应出席 监事 3 人，实际出席监事 3 人，会议由公司监事会主席谭珍友先生主持，董事会 秘书列席本次会议。本次会议的召集和召开符合法律、法规和《公司章程》的有 关规定。经与会监事认真审议，以记名投票方式表决，做出如下决议： 一、审议通过了《关于调整 2022 年限制性股票激励计划回购价格的议案》。 公司关于调整 2022 年限制性股票激励计划回购价格的事项符合相关法律法 规及公司 2022 年限制性股票激励计划等相关规定，合法、有效。同意公司关于 调整 2022 年限制性股票激励计划回购价格的事项。 表决结果：3 票同意，0 票反对，0 票弃权。 备查文件 经与会监事签名 ...

证券代码：002317 公告编号：2025-071 广东众生药业股份有限公司 第八届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十四次 会议的会议通知于 2025 年 7 月 9 日以专人和电子邮件方式送达全体董事，会议 于 2025 年 7 月 16 日在公司会议室以现场和通讯表决方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人。会议由公司董事长陈永红先生主持，全体监事、 董事会秘书列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的 有关规定。经与会董事认真审议，以记名投票方式表决，做出如下决议： 一、审议通过了《关于公司 2024 年员工持股计划首次授予部分第一个锁定 期解锁条件成就的议案》。 公司 2024 年员工持股计划（以下简称"本员工持股计划"）首次授予部分第 一个锁定期于 2025 年 7 月 16 日届满，根据本员工持股计划的相关规定，公司董 事会认为本员工持股计划首次授予部分第一个锁定期解锁条件已经成就，除一名 持有人因离职不符 ...